Ph.D., Chief Scientific Officer, Exosome Diagnostics
Biography
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.
Session Abstract – PMWC 2020 Silicon Valley
Track 4 - January 23 3.30 P.M.-4.30 P.M.
Blood/liquid biopsy-based biomarkers for the most accurate early detection of cancer are still in the early phases of development. Before these types of biomarkers/tests can be used in the clinical setting, various clinical and preclinical issues (e.g. detection sensitivity) need to be addressed. This session discusses latest advancements in the development of blood-based biomarkers and describes clinical study programs in which they are implemented, including the limitations and challenges that need to be overcome before the translation of their use for clinical purpose will be a reality.
